Expert Ratings For Omega Therapeutics
Portfolio Pulse from Benzinga Insights
Omega Therapeutics (NASDAQ:OMGA) has received mixed ratings from 6 analysts over the past three months, with a majority being bullish. The average 12-month price target is $9.83, down 4.1% from the previous $10.25. Analysts have adjusted their ratings and price targets based on recent developments. Omega Therapeutics is a biotechnology company focused on epigenetic medicines, showing strong revenue growth but facing challenges with high debt and low ROE.
June 18, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Omega Therapeutics has received mixed ratings from analysts, with a majority being bullish. The average 12-month price target is $9.83, down 4.1% from the previous $10.25. The company shows strong revenue growth but faces challenges with high debt and low ROE.
The mixed analyst ratings and the slight decrease in the average price target suggest a neutral short-term impact on the stock price. While the company shows strong revenue growth, its high debt and low ROE present challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100